Publicaciones en colaboración con investigadores/as de University of Sheffield (52)

2024

  1. High prevalence of venous thrombotic events in Cushing’s syndrome: data from ERCUSYN and details in relation to surgery

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 75-85

2023

  1. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

    The European respiratory journal, Vol. 61, Núm. 1

  2. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

    Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162

  3. Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial

    International Journal of Cardiology, Vol. 391

  4. Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel

    Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197

  5. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women

    Annals of Oncology, Vol. 34, Núm. 4, pp. 397-409

2022

  1. Code of practice needed for samples donated by trial participants

    The Lancet Oncology

  2. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

    Breast Cancer Research, Vol. 24, Núm. 1

  3. First Genotype-Phenotype Study in TBX4 Syndrome Gain-of-Function Mutations Causative for Lung Disease

    American Journal of Respiratory and Critical Care Medicine, Vol. 206, Núm. 12, pp. 1522-1533

  4. Incorporating progesterone receptor expression into the PREDICT breast prognostic model

    European Journal of Cancer, Vol. 173, pp. 178-193

  5. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

    British Journal of Sports Medicine, Vol. 56, Núm. 20, pp. 1157-1170

  6. Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

    Nature communications, Vol. 13, Núm. 1, pp. 1878

  7. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

2021

  1. Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment

    Breast cancer research : BCR, Vol. 23, Núm. 1, pp. 86

  2. Breast cancer risk factors and survival by tumor subtype: Pooled analyses from the breast cancer association consortium

    Cancer Epidemiology Biomarkers and Prevention, Vol. 30, Núm. 4, pp. 623-642

  3. Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segment-Elevation Myocardial Infarction: Insights From the COMPLETE Trial

    Circulation: Cardiovascular Interventions, Vol. 14, Núm. 8, pp. E010458

  4. First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis

    International Journal of Clinical Oncology, Vol. 26, Núm. 6, pp. 1073-1082

  5. Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element

    American Journal of Human Genetics, Vol. 108, Núm. 7, pp. 1190-1203

  6. Mendelian randomisation study of smoking exposure in relation to breast cancer risk

    British Journal of Cancer, Vol. 125, Núm. 8, pp. 1135-1145

  7. Which outcomes are most important to measure in patients with COVID-19 and how and when should these be measured? Development of an international standard set of outcomes measures for clinical use in patients with COVID-19: A report of the International Consortium for Health Outcomes Measurement (ICHOM) COVID-19 Working Group

    BMJ Open, Vol. 11, Núm. 11